153 avenue d’Italie
35 articles with Echosens
Echosens Highlights New EASL Clinical Practice Guidelines: Unprecedented Recommendation for Non-Invasive FibroScan and Care Management
Echosens, a high-technology company offering the FibroScan® family of products, announces the release of new guidelines from the European Association for the Study of the Liver, a professional association for individuals researching liver disease.
Echosens Launches New FibroScan-Based Scores Agile 3+ & Agile 4: Identifies Advanced Fibrosis and Cirrhosis, Predicts Clinical Outcomes, Improves Patient Management
Researchers present findings at EASL International Liver Congress™ 2021, June 23-26, 2021.
Echosens Announces Peer-Review Publication of Actuarial Study in American Journal of Managed Care: Positive Return on Investment of VCTE/CAP FibroScan Technology to Detect and Monitor Liver Health
Echosens , a high-technology company offering the FibroScan family of products, announces the publication of a peer-reviewed article reporting the findings of an independent assessment conducted by Santa Barbara Actuaries Inc. (SBA) to evaluate from the payer’s perspective the cost effectiveness of deploying VCTE / CAP machines (FibroScan) for detecting and monitoring fatty liver disease (FLD).
Echosens Launches SmartExam®: FibroScan® Software Upgrade Unlocks the True Power of Company’s Innovative and Differentiated Technology
New product and software update for existing devices available May 12, 2021
Echosens Launches Collaborative Relationship With Healthy Trucking of America: Improves Liver Health, Safety and Productivity of Nation’s Professional Drivers
Echosens , a high-technology company offering the FibroScan family of products, announces its collaborative relationship with Healthy Trucking of America (HTA), the leading authority on health and wellness issues for America’s truckers. The goal of the collaboration is to proactively address liver health among its 770,000 active fleets in the United States, including independent owner/operators and fleet drivers repres
Echosens Highlights Link Between Diabetes and Liver Disease, Urges Non-Invasive Detection and Monitoring of Liver Fat to Halt Disease Progression
Echosens, a high-technology company offering the FibroScan family of products, recognizes the importance of World Diabetes Day, Nov. 14, supports the International Diabetes Federation and the World Health Organization, and joins healthcare leaders worldwide to raise awareness about non-alcoholic fatty liver disease and its 70% prevalence among Type 2 diabetes patients.
Echosens Introduces FibroScan 630 Expert: Adds New Spleen Stiffness Measurement (SSM by VCTE™) for Risk Stratification of Patients with Advanced Chronic Liver Disease
Echosens, a high-technology company offering the FibroScan family of products, announces the launch of FibroScan 630 Expert in the United States, a comprehensive non-invasive solution for advanced liver disease management.
Echosens Supports October 2020 Liver Cancer Awareness Month: Cites Link to Nonalcoholic Fatty Liver Disease and Importance of Early Detection
Echosens , a high-technology company offering the FibroScan family of products, urges increased awareness of the rise of liver cancer rates, which have more than tripled since 1980, while death rates have more than doubled during this time. About 21,000 Americans are diagnosed with primary liver cancer each year—twice as common in men than in women. Risk factors include other liver diseases, including cirrhosis, chro
Echosens Emphasizes Critical Need to Monitor Liver Health, Identify Those Living with Silent Disease and Provide Follow-Up for Hepatitis C Virus
Calling for greater awareness of the 290 million people who live with viral hepatitis but are unaware of it, and in support of World Hepatitis Day (WHD), July 28, Echosens , a high-technology company offering the FibroScan family of products, urges increased vigilance around liver health. Point-of-care examinations, monitoring and ongoing assessment of liver f
Echosens Announces NICE, UK Health Technology Assessment Organization, Issues MedTech Innovation Briefing on FibroScan Liver Exam in Primary Care
Echosens , a high-technology company offering the FibroScan family of products, announces today that the National Institute for Health and Care Excellence ( NICE ), the United Kingdom’s health technology assessment body providing national guidance and advice to improve health and social care, issued a MedTech Innovation Briefing (MIB) dedicated to utilization of FibroScan non-invasive technology in the primary
Integrating Echosens’ FibroScan into MetaPhy’s Chronic Care Liver Disease Management Program Impacts Patient Outcomes, Costs, Financial Performance of Gastroenterology Practices
Echosens , a high-technology company offering the FibroScan family of products, today announces the release of its white paper authored by Dr. Reed Hogan, M.D., GI Associates (GIA) in Flowood, Mississippi, “ Understanding the Many Benefits of Comprehensive, Chronic Care Management (CCM) of Liver Dis
Echosens and NASHNET Recognize International NASH Day, June 12, 2020: Collaboration, Best Practices and Early Detection of Fatty Liver Disease
Echosens , a high-technology company offering the FibroScan family of products, joins healthcare leaders worldwide in recognition of International NASH Day , June 12, 2020, a series of virtual events via a global social media campaign, to increase awareness about non-alcoholic steatohepatitis (NASH) among the general public, at-risk patients, the medical community, public health authorities and the media. T
Battle Fatty Liver Disease and Obesity, Inform Cost-Effective Treatment Decisions: Echosens Articulates Value of Non-Invasive Diagnostic Tool, FibroScan
Echosens , a high-technology company offering the FibroScan family of products, today announces the release of its white paper, “ Two-Fold Epidemic: Fatty Liver Disease and Obesity Demand Proactive Steps, Earlier Identification of Liver Damage .” The paper examines key aspects of the entwined epidemics of obesity and fatty liver disease and highlights the importance of greater patient engagement and leveraging innovative
CDC Calls for Universal Hepatitis C Screening to Halt Advanced Liver Disease & Liver Cancer: Echosens Emphasizes Vigilance, Supports Hepatitis Awareness Month
Echosens, a high-technology company offering the FibroScan family of products, urges increased vigilance around liver health during May 2020 Hepatitis Awareness Month and calls attention to the millions of Americans from all walks of life who are living with the most common causes of viral hepatitis: hepatitis B virus and hepatitis C virus.
Echosens and MetaPhy Health Collaborate to Expand Patient-Centered Care for Chronic Liver Conditions: Gastroenterology Specialists Improve Outcomes, Lower Costs & Enhance Practice Performance
Echosens, a high-technology company offering the FibroScan family of products, announces its collaboration with MetaPhy Health to support turn-key, comprehensive chronic disease management services to gastroenterology practices for their patients with fatty liver disease.
Echosens Engages Santa Barbara Actuaries to Demonstrate Cost-effectiveness of FibroScan Non-invasive Technology for Measuring Liver Fat and Stiffness, Answers Payer Needs to Address NAFLD and NASH Epidemic
Echosens , a high-technology company offering the FibroScan family of products, has arranged an independent assessment conducted by Santa Barbara Actuaries Inc. (SBA), an actuarial and healthcare consulting firm specializing in cutting-edge predictive modeling and analytics, to determine the cost savings of FibroScan care models implemented at the point of care. FibroScan provides a non-invasive, rapid and painless ex
Echosens Calls for Increased Vigilance by Healthcare Providers to Monitor Liver Health at Point of Care, Address Obesity, Diabetes and Halt Progression of NAFLD
Download White Paper with documentation and guidance: “Understanding NAFLD and NASH in the Non-Liver Specialist Setting”
Echosens at VA’s National Veterans Small Business Engagement Meeting: Demonstrating FibroScan Benefits for Early Detection and Monitoring of Liver Disease
National Veterans Small Business Engagement, Dec. 10-11, 2019, Nashville, TN, Booth #305
Echosens FAST Score Revolutionizes the Assessment of NASH: Cost-Effective, Efficient Identification of Individuals at Risk for Active Fibrotic NASH
The FAST score is a simple combination of two physical biomarkers: liver stiffness by Vibration Controlled Transient Elastography and Controlled Attenuation Parameter together with aspartate aminotransferase, a circulating biomarker.
Echosens Releases White Paper: Federally Qualified Health Centers Effectively Address Alarming Rise in Liver Disease
Echosens, a high-technology company offering the FibroScan family of products, announces the release of its White Paper, “Empowering Federally Qualified Health Centers with Technology to Fight the Growing Burden of Chronic Liver Disease.”